Using the same experimental protocol, the more selective compounds, AT7519 and NVP-2, were utilized to evaluate the effect of CDK9 inhibition on Th1 cytokine production in PB CD4+ T cells from patients with IBD. This evidence concerns the gene CDK9 and inflammatory bowel disease.